Pre-made Emapalumab benchmark antibody ( Whole mAb, anti-IFNG therapeutic antibody, Anti-IFG/IFI/IMD69 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Emapalumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFN¦Ã) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure.
| Products Name (INN Index) | Pre-Made Emapalumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody |
|---|---|
| INN Name | Emapalumab |
| Target | IFNG |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | NovImmune SA,Swedish Orphan Biovitrum |
| Conditions Approved | Haemophagocytic lymphohistiocytosis |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNG |
| Package |
